SCHEDULE 13G/A: Casdin Capital Amends Neurogene Inc. Stake, Disclosing 8.7% Beneficial Ownership

Casdin Capital, LLC and affiliated entities have filed an amended Schedule 13G, revealing a beneficial ownership of 8.7% in Neurogene Inc. as of December 31, 2024.

Summary

• Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin collectively filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Neurogene Inc.
• As of December 31, 2024, Casdin Capital, LLC and Eli Casdin each beneficially own 1,295,361 shares of Neurogene Inc. Common Stock, representing 8.7% of the class.
• Casdin Partners Master Fund, L.P. and Casdin Partners GP, LLC each beneficially own 1,075,000 shares, representing 7.2% of the class.
• All reporting persons share voting and dispositive power over their respective reported shares.
• The securities were not acquired or held for the purpose of changing or influencing control of Neurogene Inc., except for activities solely in connection with a nomination under Rule 14a-11.
• The principal executive offices of Neurogene Inc. are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
• The reporting persons' business office is located at 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a routine regulatory filing.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an investment firm in a publicly traded biotechnology company. Such filings provide transparency regarding institutional holdings and can sometimes signal investor confidence or strategic interest in the sector, particularly in innovative areas like gene therapy, which Neurogene Inc. is involved in.

Related Party Transactions

• All securities reported are directly owned by advisory clients of Casdin Capital, LLC. Casdin Partners Master Fund, L.P. is identified as an advisory client that may beneficially own more than 5% of the Common Stock, indicating an internal relationship within the Casdin Capital group.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Investors: Offers insight into the holdings of a prominent investment firm, potentially signaling confidence or strategic interest in Neurogene Inc.

Key Dates

Keywords

Neurogene Inc., Casdin Capital, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Gene Therapy